Explore All 368 Buyout (LBO, MBO, MBI) Packaging Deals - Search the Database Free
M&A Deal Summary |
|
|---|---|
| Date | February 3, 2017 |
| Target | PPC Flexible Packaging |
| Sector | Packaging |
| Buyer(s) | Morgan Stanley Capital Partners |
| Deal Type | Buyout (LBO, MBO, MBI) |
FILTER BY
| Category | Private Equity Firm |
|---|---|
| Founded | 1985 |
| Size | Large |
| Type | Sector Agnostic |
Morgan Stanley Capital Partners (MSCP) is the private investment arm of financial services firm and investment bank Morgan Stanley. MSCP looks to partner with founders looking to leverage Morgan Stanley's resources, as well as fund corporate carveouts, recapitalizations, buyouts, and industry consolidations. Areas of interest include business services, industrials, education, consumer products/services, food/beverage, retail, healthcare, and packaging. MSCP primarily targets businesses operating in North America valued between $75 and $750 million. Morgan Stanley Capital Partners is based in New York City.
| Deal Context for Buyer | # |
|---|---|
| Overall | 24 of 52 |
| Sector: Packaging | 1 of 2 |
| Type: Buyout (LBO, MBO, MBI) | 8 of 13 |
| State: Illinois | 1 of 1 |
| Country: United States | 21 of 48 |
| Year: 2017 | 1 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2016-10-06 |
24 Seven
New York, New York, United States 24 Seven is a human capital management firms specializing in the placement of freelance and full-time creative, marketing and digital talent. Through a network of nine U.S. offices and two international offices, the company delivers advertising, creative, marketing and interactive / digital professionals for freelance and permanent placements. 24 Seven was founded in 2000 and is based in New York, New York. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-07-31 |
DiscoveRx
Fremont, California, United States DiscoveRx Corp. is an innovative company that develops, manufactures, and commercializes reagents, complete cell-based assay kits, profiling and screening services as well as other disruptive solutions for the drug discovery, screening, and life science markets. EFC technology is a proven, established screening platform in most major pharmaceutical companies. With over 900 stable cell lines, 4500 drug discovery assays and kits, and both custom and off-the shelf services, DiscoverX is one of the most trusted and utilized drug discovery portfolios in the world. |
Sell | - |
